To facilitate analysis of high sample volumes, an extraction, derivatization and gas chromatographic-mass spectrometric analysis method was developed to simultaneously determine amphetamine (AMP), methamphetamine (MAMP), 3,4-methylenedioxyamphetamine (MDA) 3,4-methylenedloxymethamphetamine (MDMA), and 3,4-methylenedioxyethylamphetamine (MDEA) in urine. This method utilized a positive-pressure manifold cation-exchange polymerbased solid-phase extraction followed by elution directly into automated liquid sampler (ALS) vials. Rapid derivatization was accomplished using heptafluorobutyric anhydride (HFBA). Recoveries averaged 90% or greater for each of the compounds. Limits of detection were 62.5 ng/mL (AMP and MDEA), 15.6 ng/mL (MAMP), and 31.3 ng/mL (MDA and MDMA) using a 2-mL sample volume. The method was linear to 5000 ng/mL for all compounds using MDMA-ds and MAMP-dt4 as internal standards. Over 200 human urine samples previously determined to contain the target analytes were analyzed using the method. Excellent agreement was seen with previous quantitations. The method was challenged with 75 potentially interfering compounds and no interferences were seen. These interfering compounds included ephedrine, pseudoephedrine, phenylpropanolamine, and phenethylamine. The method resulted in dramatic reductions in processing time and waste production.
Amphetamine (AMP), methamphetamine (MAMP), and 3,4-methylenedioxyamphetamine (MDA)/3,4-methylenedioxymethamphetamine (MDMA) (Ecstasy) usage have been on the rise nationwide and have garnered increasing media attention. The increasing usage of MDMA is especially alarming because of its perception as a safe drug and its significant long-term deleterious side effects likely due to its effect on serotonin dependent brain activities (1) . Within the military, sharp increases in the positive rates for MDMA have been noted in all four branches (2) . As such, the increasing workload associated with detecting and confirming sympathomimetic amine abuse has necessitated improving the efficiency of processing methods.
Though MDMA and MAMP may be more widely used than AMP and MDA, AMP is an excreted metabolite of MAMP (3) and MDA is one of multiple metabolites of MDMA (4) . This coupled with the added complication of excluding the use of R-(-)-MAMP has typically led laboratories to analyze for all of the compounds.
Multiple methods have been published for the determination of AMP, MAMP, MDA, and MDMA (5) (6) (7) (8) (9) (10) (11) (12) (13) . Simultaneous determinations of all of these compounds in hair and urine have been published by Kintz et al. (13) and Hensley and Cody (8) , respectively. Both of these methods utilize liquid-liquid extractions and as such are less efficient than those that employ solid-phase extraction.
The current method for the analysis of AMP/MAMP at the Navy Drug Screening Laboratory (Jacksonville, FL) uses a liquid-liquid extraction and derivatization with 4-carbethoxyhexafluorobutyryl chloride (5) . Although this method provides excellent results, two aliquots must be analyzed to determine both AMP/MAMP and MDA/MDMA concentrations and a large quantity of chlorinated solvent must be used in the extraction. A more optimal method would allow for the simultaneous determination of all compounds of interest and a reduction in waste production.
Numerous papers have been published addressing the potential for interferences from other over-the-counter (OTC) sympathomimetic amines (6, 9, 11) . Thus, the developed method employs a sodium periodate pretreatment to eliminate ephedrine, pseudoephedrine, and phenylpropanolamine (PPA) from the sample.
The purpose of this study was to develop a method to efficiently determine AMP, MAMP, MDA, MDMA, and MDEA in urine samples and demonstrate its accuracy, precision, linearity, and reproducibility.
Methods

Materials
Extractions utilized a Speedisk | 48 pressure processor positive pressure extraction manifold (SPEWare, San Pedro, CA) and polymer-based cation/mixed bed exchange extraction columns (Cerex | CLIN II, 35 mg, 3-mL capacity). Methanol, All analyses were performed in selected ion monitoring (SIM) mode using the ions, quantitation, and identity ratios indicated in Table I . Molecular justification of these ions is presented in Figure 2 and full spectrum scans of neat standards derivatized as described are presented in Figure 3 . The m/z 118, 254, and 210 ions were the result of McLafferty rearrangements (14, 15) . The m/z 192 ion is the result of the extrusion of CO and HF as indicated in Figure 2 . Using several deuterium labeled amphetamine analogues obtained from Cerilliant, conclusive demonstration of the portions of the amphetamine molecule involved. AMP-d11 has an m/z 196 indicating the inclusion of four deuteriums from the parent molecule. Ring-labeled AMP has a mass-tochange ratio of only 192 (no deuteriums included) and a differently labeled AMP-d8 lacking one deuterium in the branch exhibits an rn/z 195 ion (inclusion of three deuteriums). Fragmentation patterns of variously deuterated amphetamine analogues indicate that the 192 fragment contains the two indicated carbons from the parent compound. Thus, the m/z 192 ion is a useful qualifier ion that has relevance to the target compound.
Periodate treatment
To 2 mL of urine in a 13 x 100 tube, 0.1 mL of internal standard (0.01 mg/mL MAMP-dz4 and 0.01 mg/mL MDMA-ds), 0.2 mL of 12N NaOH, and 1.0 mL of 0.4M sodium periodate were added. Tubes were capped and incubated for 15 rain at 50-60~ The samples were then allowed to cool at room temperature.
Extraction
The samples were poured into 3-mL columns and placed onto the Speedisk. Positive pressure (2-5 psi) was applied to the columns. Next, I mL of water was applied to the column followed by i mL 0.1M HC1. Positive pressure (2-5 psi) was applied after each reagent addition and the column dried for 2 rain at 25 psi. The column was then washed with I mL methanol and i mL ethyl acetate. Again the column was dried for 2 rain at 25 psi. The target compounds were eluted into automated liquid sampler (ALS) vials with the addition 1.0 mL of ethyl acetate/methanol/ammonium hydroxide (80:20:2, v/v) to the column. Prior to drying, 0.050 mL of 1% HC1 in methanol was added to the sample to reduce the potential to volatilize the target compounds. Samples were then evaporated to dryness under a stream of nitrogen.
Derivatization
Samples were derivatized using 0.035 mL HFBA in 0.025 mL ethyl acetate added to the ALS vials. Samples were capped mixed and incubated for 10 rain at 60-70~ Samples were removed from the heat block, allowed to cool at room temperature, and then evaporated to dryness. Samples were then reconstituted with 0.100 mL of ethyl acetate for GC-MS analysis.
Results and Discussion
Recovery
Method recovery was assessed by analyzing two groups of three drug-free urine samples spiked with AMP/MAMP/ MDA/MDMA/MDEA at 250 ng/mL as follows: the first set had internal standard added at the beginning of the extraction, the second set had the internal standard added to the ALAS vials after elution of the target compounds was complete. An average was taken of the internal standard area results for the two groups of samples. Dividing these two numbers resulted in a measure of recovery. Recoveries were 94%, 90%, 92%, 90%, and 94% for AMP, MAMP, MDA, MDMA, and MDEA respectively.
Interference
Samples containing 500 ng/mL of each of the target analytes Table II were spiked with various combinations of the potentially interfering compounds ranging in concentration from 0.4 to 2.5 mg/L (Table II) . Drug-free urine was also spiked with the compounds listed in Table II . An additional set of four samples contained AMP at 550 ng/mL and MAMP at 600 ng/mL and high concentrations of phenethylamine added (greater than 50,000 ng/mL). All of the samples were extracted as described and analyzed to determine the potential for the compounds to interfere with the assay. None of the compounds examined interfered with the target compounds. All ratios were within • 20% of the calibrator. Of particular interest, during initial method development, phenethylamine was found to co-elute with AMP and had a common ion of m/z 91. However when m/z 91 was replaced with m/z 192, the mean quantitations resulted as AMP 526 ng/mL and MAMP as 652 ng/mL with acceptable identity ratios. Thus, the interference potential from phenethylamine was eliminated.
Other sympathomimetic amines that may potentially confound the analysis of the target compounds such as ephedrine, pseudoephedrine were successfully separated chromatographically from the target analytes and the periodate pretreatment reduced or eliminated the presence of these compounds in samples ( Figure 1 ). Confusion of these compounds with the targets or confusion of the target compounds was eliminated in this method by having unique ion sets for each of the compounds. Additionally, chromatographic separation of all of the compounds is such that common ions, such as m/z 254 addressed by Dasgupta and Gardner (6) , are unquestionably resolved (Figure 1 ).
Linearity and detection limit
The limit of detection (LOD) and limit of quantitation (LOQ) of the method were determined by analyzing nine levels of samples in quadruplicate spiked with AMP/MAMP/ MDA/MDMA/MDEA ranging from 7.81 to 5000 ng/mL. Extraction and GC-MS analysis were performed as previously described. The LOD was determined to be the lowest concentration at which all replicates produced results with all analyte qualifying ion ratios within acceptable limits (+ 20% of the calibrator ratios). The LOQ was determined to be the lowest concentration at which the analyte qualifying ion ratios (Table  I) were within the + 20% limit established by the calibrator and the determined concentration was within • 10% of the expected concentration. The determined LODs listed in Table  III .
The limit of linearity was established by analyzing increasing concentrations of the target analytes until one or more of the qualifying ion ratios failed or the determined concentration fell outside • 10% of the expected concentration. The assay was linear to 5000 ng/mL for all compounds (Figure 4 ) with the mean results within 10% of the expected concentration. Some increase in variation was seen between replicates at concentration levels above 2000 ng/mL, but this variation did not detract from the linearity of the assay above 2000 rig/mE. This range of linearity provides wide coverage, including much of the reported urine concentrations of MDA and MDMA (14) .
Precision
The within-run precision was accessed by analyzing 10 drugfree urine samples spiked with AMP/MAMP/MDA/MDMA/MDEA at the GC-MS cutoff concentration (500 ng/mL). Extraction and GC-MS analysis was performed as previously described. The precision samples yielded an average responses of AMP 449 ng/mL (%CV 7.6), MAMP 504 ng/mL (%CV 1.4), MDA 484 ng/mL (%CV 2.3), MDMA 489 ng/mL (%CV 1.4), and MDEA 492 ng/mL (%CV 0.8). Excellent correlation was seen between measured and expected results for control materials over a wide range of concentrations (Figure 3) . The between-run precision, assessed over the course of 10 separate batches prepared by 3 different technicians on different days, produced %CV results of 5.1, 6.0, 9.5, 2.4, and 15.8 for AMP, MAMP, MDA, MDMA, and MDEA, respectively, for positive control at 250 ng/mL each.
Comparative study
One hundred 1-3-year-old specimens were used in this analysis. Samples had been stored frozen, and once defrosted, were stored refrigerated. These samples contained a range of concentrations and combinations of the target analytes. Extraction and GC-MS analysis was performed as previously described. The quantitation using the described method was performed using all controls and acceptance criteria standard in the laboratory. Figure 5 presents regression results of the analyses compared to the previous method results for the 100 samples. The regression results indicate excellent agreement between the previous method and the described method. A summary of the results of a Student's t-test comparing the previous method results with the described method results in Table IV indicates no significant difference between the method results. Thus, the new assay is reproducible in comparison to previous methods used in our laboratory.
One hundred samples that produced screening responses between half the screening cutoff and the cutoff were also analyzed. These samples demonstrated no interferences from OTC medications. Only one sample demonstrated the presence of methamphetamine at a concentration of 122 ng/mL. Otherwise, all of the samples were negative. These results indicate that a wide range of screening results above and below the screening cutoff produce appropriate results with this method and that confounding compounds that produce elevated screening results do not produce inappropriate results by this extraction and derivatization method. 
Conclusions
The reported method provides a sensitive, accurate, and simultaneous assay for AMP/MDA/MDMA/MDEA in urine. Good chromatographic performance was observed in controls as well as native samples. No interferences from a wide variety of compounds were observed. Specifically, the interference potential from structurally related sympathomimetic amines including ephedrine, pseudoephedrine, PPA, and phenethylamine was Previous method result (ng/mL) Figure 5 . Regression fits of the 100 samples analyzed by the previous method and the method described in this paper. R2 values for each of the compounds are included as well as the slope of the regression fit line 9 A slope of 1 indicated excellent agreement between the two methods. No native samples confirmed for MDEA were available for this study 9 eliminated by monitored ion choice, chromatographic separation and periodate pretreatment (6, 9, 11) . Thus, the common m/z 254 ion between MAMP and ephedrine/pseudoephedrine was minimized because of their chromatographic separation (6) . Though this method was developed without the use of a deuterated internal standard for amphetamine and MDA in an effort to optimize the cost efficiency of the method, these internal standards could be easily used and may provide improved performance in individual circumstances.
The positive pressure manifold has positions for 48 controls or samples. Our experience has been that a batch can be easily processed from sample set up and paper work handling to placing samples on the GC-MS in approximately 2 h. The use of the positive pressure manifold and the polymer-based columns greatly reduced the waste production of the assay by eliminating the preconditioning steps and utilizing minimal solvent volumes. The aqueous urine waste could be isolated from the organic solvent wastes there by further reducing disposal costs. The method produced approximately 3 mL of organic solvent waste per sample and eliminates over 20 mL per sample of chlorinated solvents used with the previous methodology. The reduction in chlorinated solvents is of particular note as these solvents are increasingly regulated which increases their cost of handling and disposal.
Because of the high flow rates through the columns and minimal steps, the assay was very rapid. The small footprint and contained nature of the positive pressure manifold reduced worker exposure to hazards. The elution of the samples and their derivatization directly into the ALS vials eliminated glassware transfers, ensured the integrity of the samples, and simplified labeling of the vials.
